Form 8-K - Current report:
SEC Accession No. 0001193125-25-004097
Filing Date
2025-01-10
Accepted
2025-01-10 07:47:43
Documents
17
Period of Report
2025-01-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d921741d8k.htm   iXBRL 8-K 25707
2 EX-99.1 d921741dex991.htm EX-99.1 36073
6 GRAPHIC g921741g0110050724762.jpg GRAPHIC 812
7 GRAPHIC g921741g49c07.jpg GRAPHIC 11699
8 GRAPHIC g921741g88j88.jpg GRAPHIC 9116
  Complete submission text file 0001193125-25-004097.txt   209745

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rprx-20250110.xsd EX-101.SCH 2856
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rprx-20250110_lab.xml EX-101.LAB 17235
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rprx-20250110_pre.xml EX-101.PRE 10816
20 EXTRACTED XBRL INSTANCE DOCUMENT d921741d8k_htm.xml XML 3557
Mailing Address 110 EAST 59TH STREET NEW YORK NY 10022
Business Address 110 EAST 59TH STREET NEW YORK NY 10022 (212) 883-0200
Royalty Pharma plc (Filer) CIK: 0001802768 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39329 | Film No.: 25520464
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)